peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

cortical neuropeptide mix

Cortexin

Published evidence · coverage incomplete

Anatomy in the research

Anatomy evidence is still being assembled.

These are anatomical mentions in cited research—not established treatment targets or proof of benefit in people.

This publication has no anatomy passages that meet our source-linking checks yet. Read the available findings ↓

General anatomy view only. No peptide-specific structures are highlighted.

At a glance

What is it—and why does it matter?

An introduction is not yet available. The findings below address specific research questions, not a complete account of this peptide.

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

How does it work?

Target, response, and disposition.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

What has been studied?

What the evidence says.

Study findings

The primary effectiveness definition in the methods was a dichotomized modified Rankin Scale outcome (0–2) measured at 90 days.

Sources[1]pubmed[Therapeutic equivalence of intravenous and intramuscular dosage forms of Cortexin in ischemic strokes].The evaluation of the effectiveness of the studied Cortexin dosage forms was defined as the proportion of patients who reached 0-2 on the modified Rankin scale (mRS) on the 90th day of the study.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The evaluation of the effectiveness of the studied Cortexin dosage forms was defined as the proportion of patients who reached 0-2 on the modified Rankin scale (mRS) on the 90th day of the study.”

    [Therapeutic equivalence of intravenous and intramuscular dosage forms of Cortexin in ischemic strokes]. · MATERIAL AND METHODS

    pubmed:41524350:768403ec5bb8:768403ec5bb8

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, identity, interaction, mechanism, regulatory, safety
  • 69 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (42), assurance_score_below_0.72 (15), current_regulatory_source_required (12), extraction_ambiguity (64), high_risk_requires_regulatory_or_two_independent_sources (27), no_direct_support (57)
  • A source-backed introductory overview is not yet available.

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. [Therapeutic equivalence of intravenous and intramuscular dosage forms of Cortexin in ischemic strokes]. ↗

    pubmed · published 2025-01-01 · retrieved 2026-09-03T08:51:04Z

Publication history and provenance

Version 1 · Automated assessment · 2026-09-03T08:51:04Z

05209491b4f25177a00de05d8754b4d12f29198c9a918c52f8052dfe58b8e197